Nova Steroid Pharma Co.,Ltd
Ligandrol(LGD4033) Sarms Powder For Bodybuilding CAS:1165910-22-4

Ligandrol(LGD4033) Sarms Powder For Bodybuilding CAS:1165910-22-4

Ligandrol, codenamed LGD-4033, is a third-generation Selective Androgen Receptor Modulator (SARM) developed by Ligand Pharmaceuticals in collaboration with Viking Therapeutics. Initially researched for age-related muscle wasting and osteoporosis, it has gained prominence for its ability to selectively activate androgen receptors (AR) in muscle and bone tissues while sparing organs like the prostate and liver.

Send Inquiry
Description

     Ligandrol, codenamed LGD-4033, is a third-generation Selective Androgen Receptor Modulator (SARM) developed by Ligand Pharmaceuticals in collaboration with Viking Therapeutics. Initially researched for age-related muscle wasting and osteoporosis, it has gained prominence for its ability to selectively activate androgen receptors (AR) in muscle and bone tissues while sparing organs like the prostate and liver. Unlike traditional anabolic steroids, Ligandrol's non-steroidal structure and tissue specificity offer a safer profile, making it a focal point in both clinical research and athletic communities. This guide explores its mechanisms, applications, and controversies, emphasizing novel insights not covered in prior discussions of other SARMs.

SARMs-BANNERS-8

Molecular Structure and Mechanism: Precision in Design

    Chemical Identity

    ●IUPAC Name: (2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide

    ●Molecular Formula: C₁₄H₁₂F₃N₃O₃

    ●Molecular Weight: 343.26 g/mol

    ●Solubility: Hydrophobic (soluble in DMSO, PEG-300; negligible water solubility).

    Mechanistic Innovations

    LGD-4033 binds ARs with high affinity (Ki = 1.2 nM), functioning as a full agonist in muscle and bone but showing minimal activity in androgenic tissues. Key pathways include:

    ●mTORC1 Activation: Stimulates ribosomal S6 kinase, enhancing protein synthesis.

    ●Osteoblast Differentiation: Upregulates Wnt/β-catenin signaling, increasing bone mineral density (BMD) without accelerating bone resorption.

    ●Anti-Catabolic Effects: Inhibits glucocorticoid-induced muscle breakdown via AR interference.

    Unique Pharmacokinetics

    ●Oral Bioavailability: ~94% in primates due to nitro-group shielding from hepatic CYP3A4 metabolism.

    ●Blood-Brain Barrier Penetration: Modulates central ARs to enhance neuromuscular coordination and appetite regulation, a trait less common in other SARMs.

Applications: From Medical Therapy to Biohacking

    Therapeutic Innovations

    1.Cancer Cachexia:

    ●In Phase II trials, 1 mg/day for 21 days increased lean mass by 1.3 kg in advanced cancer patients, outperforming placebo by 300%.

    2.Osteoporosis Rehabilitation:

    ●Improved trabecular BMD by 12% in osteopenic rats (0.3 mg/kg/day for 8 weeks), with potential applications in postmenopausal women.

    3.Burn Recovery:

    ●Accelerates donor site healing via AR-mediated keratinocyte migration and collagen III synthesis.

    Athletic and Aesthetic Uses

    ●Lean Mass Accretion: Users report 4–7 lbs of dry muscle gain over 8 weeks at 5–10 mg/day.

    ●Strength Enhancement: Powerlifters note 8–12% improvements in 1RM lifts due to enhanced myosin ATPase efficiency.

    ●Injury Mitigation: Reduces immobilization-induced atrophy by 40% in preclinical models.

    Emerging Frontiers

    ●Neurodegenerative Research: Preserves motor neurons in ALS models via AR-dependent SOD1 stabilization.

    ●Metabolic Flexibility: Enhances insulin sensitivity in adipose tissue through PI3K-Akt crosstalk.

    ●Space Medicine: NASA-funded studies explore its role in countering microgravity-induced muscle wasting.

Benefits Over Traditional Anabolics

    ●Tissue Selectivity: 10:1 anabolic-to-androgenic ratio, minimizing prostate enlargement or hair loss.

    ●Non-Hepatotoxic: Lacks 17α-alkylation, avoiding liver strain seen in oral steroids.

    ●Muscle Memory: Upregulates MyoD expression, enhancing rebound growth post-cycle.

Dosage and Cycle Design: Balancing Efficacy and Safety

    Clinical and Anecdotal Protocols

    ●Medical Use: 1–2 mg/day for muscle wasting or osteoporosis.

    ●Performance Enhancement: 5–10 mg/day for 8–12 weeks (split AM/PM doses).

    ●Female-Specific Use: 2.5 mg/day for lean gains without virilization (clitoromegaly risk <1%).

    Synergistic Stacks

    1.LGD-4033 + MK-677: Combines AR-driven hypertrophy with GH-mediated recovery (5 mg LGD + 25 mg MK-677).

    2.LGD-4033 + Cardarine: Targets fat loss and endurance (5 mg LGD + 20 mg GW501516).

    3.Cognitive Stack: LGD-4033 (5 mg) + Lion's Mane (1g) for neuromuscular and neuroprotective benefits.

Pharmacokinetics: Timing and Metabolism

    ●Absorption: Tmax = 1–2 hours; bioavailability unaffected by food but delayed by high lipids.

    ●Half-Life: ~24–36 hours, enabling once-daily dosing.

    ●Metabolism: Hepatic UGT2B17 glucuronidation; excreted renally (65%) and fecally (35%).

    Genetic Note: UGT2B17 polymorphisms (common in East Asians) reduce clearance by 40%, necessitating lower doses.

Post-Cycle Therapy (PCT): Restoring Homeostasis

    ●SERM Protocols: Tamoxifen (20 mg/day) or Enclomiphene (12.5 mg/day) for 3–4 weeks post-cycle.

    ●Lipid Rehabilitation: Bergamot extract (1,000 mg/day) or omega-3s (4g EPA/DHA) for 6 weeks.

    ●Muscle Retention: Leucine (5g/day) to sustain mTOR activity post-cycle.

Risks and Ethical Considerations

    Health Risks

    ●HPTA Suppression: Doses ≥5 mg/day reduce LH/FSH by 50–70%, necessitating PCT.

    ●Lipid Dysregulation: Lowers HDL by 20% and elevates LDL by 15% in 12-week cycles.

    ●AR Desensitization: Chronic use (>6 months) downregulates muscle AR density by 30%.

    Legal and Ethical Challenges

    ●WADA Status: Banned since 2015 for performance enhancement.

    ●Regulatory Ambiguity: Marketed as a "research chemical," evading FDA oversight despite human use.

    ●Environmental Impact: Non-biodegradable metabolites detected in aquatic ecosystems.

    Future Directions: Innovation and Responsibility

    ●Prodrug Development: LGD-4033 palmitate for weekly dosing via subcutaneous depots.

    ●Gene Editing Synergy: CRISPR-enhanced AR expression in satellite cells for amplified hypertrophy.

    ●Clinical Trials: Urgent need for Phase III studies in cachexia and osteoporosis populations.

Clinical data

Trade names

LGD4033,Ligandrol,VK5211

CAS

1165910-22-4

Molar mass

338.253

MF

C14H12F6N2O

Purity

Above 98%

Apprarance

White crystal powder

 

Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885

 

Conclusion: A Paradigm Shift in Anabolic Therapy

    Ligandrol represents a watershed in androgen therapeutics, offering muscle-specific benefits with minimized risks. However, its experimental status and regulatory gray areas demand cautious optimism. As research evolves, LGD-4033 may redefine treatments for muscle wasting, aging, and metabolic health-provided ethical and scientific rigor guide its journey.

Hot Tags: ligandrol(lgd4033) sarms powder for bodybuilding cas:1165910-22-4, China ligandrol(lgd4033) sarms powder for bodybuilding cas:1165910-22-4 manufacturers, suppliers, factory, SR9009, RAD140, OTR-AC, MK2866 Treat Muscular Dystrophy and Osteoporosis, LGD3303, AC 262 Selective androgen receptor modulator

Inquiry
goTop

(0/10)

clearall